메뉴 건너뛰기
Dermatitis
Volumn 20, Issue 5, 2009, Pages 271-274
Methylphenidate patch-test protocol and irritancy threshold determination in healthy adult subjects
Author keywords

[No Author keywords available]
Indexed keywords

METHYLPHENIDATE; PETROLATUM;
EID: 70350303808     PISSN: 17103568     EISSN: None     Source Type: Journal    
DOI: 10.2310/6620.2009.09001     Document Type: Article
Times cited : (6)
References (15)
  • 1
    • 20444412281 scopus 로고    scopus 로고
    • Molecular genetics of attention-deficit/hyperactivity disorder
    • Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313-1323
    • (2005) Biol Psychiatry , vol.57 , pp. 1313-1323
    • Faraone, S.V.1    Perlis, R.H.2    Doyle, A.E.3
  • 2
    • 0031870219 scopus 로고    scopus 로고
    • The neurobiology of attention-deficit/hyperactivity disorder
    • Zametkin AJ, Liotta W. The neurobiology of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1998;59 Suppl 7:17-23.
    • (1998) J Clin Psychiatry , vol.59 , Issue.SUPPL. 7 , pp. 17-23
    • Zametkin, A.J.1    Liotta, W.2
  • 3
    • 0004235298 scopus 로고    scopus 로고
    • American Psychiatric Association 4th ed. (Text revision DSM-IV-TR). Washington (DC): American Psychiatric Association
    • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (Text revision DSM-IV-TR). Washington (DC): American Psychiatric Association; 2000.
    • (2000) Diagnostic and Statistical Manual of Mental Disorders
  • 4
    • 33947140874 scopus 로고    scopus 로고
    • National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder
    • DOI 10.1542/peds.2006-2089O
    • Visser SN, Lesesne CA, Perou R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics 2007;119 Suppl 1:S99-106. (Pubitemid 46397953)
    • (2007) Pediatrics , vol.119 , Issue.SUPPL. 1
    • Visser, S.N.1    Lesesne, C.A.2    Perou, R.3
  • 5
    • 3242880979 scopus 로고    scopus 로고
    • Attention-deficit/hyperactivity disorder in adults
    • Wilens TE, Faraone SV, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA 2004;292:619-623
    • (2004) JAMA , vol.292 , pp. 619-623
    • Wilens, T.E.1    Faraone, S.V.2    Biederman, J.3
  • 6
    • 34250797891 scopus 로고    scopus 로고
    • Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder
    • AACAP Work Group on Quality Issues
    • Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921.
    • (2007) J Am Acad Child Adolesc Psychiatry , vol.46 , pp. 894-921
    • Pliszka, S.1
  • 8
    • 33744827954 scopus 로고    scopus 로고
    • The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder
    • Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-657
    • (2006) J Am Acad Child Adolesc Psychiatry , vol.45 , pp. 642-657
    • Pliszka, S.R.1    Crismon, M.L.2    Hughes, C.W.3
  • 9
    • 3042622074 scopus 로고    scopus 로고
    • Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder
    • American Academy of Pediatrics
    • American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033-1044
    • (2001) Pediatrics , vol.108 , pp. 1033-1044
  • 10
    • 70350294661 scopus 로고    scopus 로고
    • Noven Pharmaceuticals Inc Available at: accessed January 3, 2008
    • Noven Pharmaceuticals Inc. DOT MatrixH technology. Available at: http://www.daytrana.com (accessed January 3, 2008).
    • DOT MatrixH Technology
  • 11
    • 44849099627 scopus 로고    scopus 로고
    • Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/ hyperactivity disorder
    • Wilens TE, Boellner SW, López FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008;47:700-708
    • (2008) J Am Acad Child Adolesc Psychiatry , vol.47 , pp. 700-708
    • Wilens, T.E.1    Boellner, S.W.2    López, F.A.3
  • 12
    • 33751230216 scopus 로고    scopus 로고
    • Cutaneous reactions to transdermal therapeutic systems
    • Musel AL, Warshaw EM. Cutaneous reactions to transdermal therapeutic systems. Dermatitis 2006;17:109-122
    • (2006) Dermatitis , vol.17 , pp. 109-122
    • Musel, A.L.1    Warshaw, E.M.2
  • 13
    • 41649096344 scopus 로고    scopus 로고
    • Practical management of cutaneous reactions to the methylphenidate transdermal system: Recommendations from a dermatology expert panel consensus meeting
    • Warshaw EM, Paller AS, Fowler JF, Zirwas MJ. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting. Clin Ther 2008;30:326-337
    • (2008) Clin Ther , vol.30 , pp. 326-337
    • Warshaw, E.M.1    Paller, A.S.2    Fowler, J.F.3    Zirwas, M.J.4
  • 14
  • 15
    • 13844262799 scopus 로고    scopus 로고
    • North American Contact Dermatitis Group patch-test results, 2001-2002 study period
    • Pratt MD, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch-test results, 2001-2002 study period. Dermatitis 2004;15:176-183
    • (2004) Dermatitis , vol.15 , pp. 176-183
    • Pratt, M.D.1    Belsito, D.V.2    DeLeo, V.A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.